ReviewInternal medicine (Tokyo, Japan)2026
Therapeutic Mechanisms of Traditional Kampo Medicines in the Management of Mild COVID-19 through Gut Microbiota Modulation.
Review in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Persistent SARS-CoV-2 Infection in an Immunocompromised Host Treated Successfully With the Japanese Herbal Medicine, Mao-to: A Case Report.The American journal of case reports · 2026Article
- Research progress in the inhibitory mechanisms of traditional Chinese medicine therapies against influenza A.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite antiviral administration, a small number of patients still suffer from prolonged and severe COVID-19 owing to excessive inflammation. Traditional Kampo medicines (TKMs) with a heat-clearing effect have anti-inflammatory effects, such as a reduced NF-κB activity, and rarely cause serious side effects when administered for a short period of time. After oral administration, TKMs interact with the gut microbiota, producing two types of metabolites: metabolites from the gut microbiota (of food and host origin) and TKM compounds transformed by the gut microbiota. Both metabolites decreased the levels of pro-inflammatory cytokines. TKM compounds transformed by the gut microbiota may exhibit superior bioavailability compared with their precursors. In this review, we assessed the mechanism by which bioactive substances with anti-inflammatory effects, such as berberine, baicalin, saikosaponin, kaempferol, and short-chain fatty acids, are effective in treating respiratory symptoms after COVID-19 infection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.